AgomAb Therapeutics NV - ADRs representing one common share

Moat components assessed for a pre‑revenue biotech: Intangible assets and IP (weight 50%, score 55): portfolio includes composition‑of‑matter and method‑of‑use protections for ontunisertib families and a U.S. composition‑of‑matter patent for AGMB‑447 through at least 2041; ontunisertib has FDA Fast Track status and Phase 2b design aligned with FDA.

These are real but early‑stage moats that depend on clinical success. Switching costs (weight 15%, score 10): low for prescribers and payers; adoption will hinge on clear clinical benefit and safety. Network effects (weight 0%, score 0): none.

Cost advantages (weight 15%, score 15): organ‑restricted delivery could lower systemic toxicities versus systemic TGF‑β/ALK5 inhibition, potentially easing long‑term safety management, but not yet proven as a durable cost edge.

Efficient scale (weight 20%, score 25): if first to market in FSCD, limited competitive capacity could create local efficient scale; however, this is contingent on clinical success and regulatory precedent. Weighted outcome yields a modest moat given binary risk and absence of commercial entrenchment.